Reslizumab
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Reslizumab |
| DrugBank ID | DB06602 |
| Brand Names (EU) | Cinqaero |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.53% |
Approved Indication (EMA)
Cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | thrombocytopenia due to immune destruction | 99.53% | DL |
| 2 | primary release disorder of platelets | 99.25% | DL |
| 3 | pseudo-von Willebrand disease | 98.98% | DL |
| 4 | autoimmune thrombocytopenic | 98.89% | DL |
| 5 | Glanzmann thrombasthenia | 98.62% | DL |
| 6 | neonatal thrombocytopenia | 98.07% | DL |
| 7 | autosomal thrombocytopenia with normal platelets | 97.96% | DL |
| 8 | Evans syndrome | 97.89% | DL |
| 9 | filariasis | 96.22% | DL |
| 10 | acne keloid | 95.29% | DL |
| 11 | neonatal dermatomyositis | 94.89% | DL |
| 12 | dermatitis | 94.79% | DL |
| 13 | amyopathic dermatomyositis | 94.65% | DL |
| 14 | acrodermatitis chronica atrophicans | 94.26% | DL |
| 15 | mixed-type autoimmune hemolytic anemia | 94.14% | DL |
| 16 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | 94.09% | DL |
| 17 | hydroa vacciniforme, familial | 94.00% | DL |
| 18 | drug-induced autoimmune hemolytic anemia | 93.83% | DL |
| 19 | syndromic constitutional thrombocytopenia | 93.57% | DL |
| 20 | neonatal autoimmune hemolytic anemia | 92.93% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.